Despite the presence of BRAF and NRAS mutations in patients with CLL, targeted BRAF-MEK inhibition therapy has not been shown to be effective but may potentially be helpful with prognostication [12]. The gene discussed is NRAS; the disease is B-cell chronic lymphocytic leukemia.